OptiPin
Are peptides legal in the US? The 2026 FDA status
In 2023 the FDA placed roughly 19 peptides - including BPC-157 and TB-500 - into 503A Category 2, removing them from compounding eligibility. In 2026 that decision is being reconsidered, and on July 23-24, 2026 an FDA advisory committee reviews seven of them. This is a plain explainer of where things actually stand - and, importantly, what has not changed yet. It is educational, not legal or medical advice.
- • Nothing has formally changed yet. The 2023 Category 2 placements are still in effect; the 2026 reconsideration is in progress, not finished.
- • The direction of travel is toward broader access. A Feb 2026 HHS announcement signaled intent to move ~14 peptides from Category 2 back toward Category 1.
- • July 23-24, 2026 is the next hinge. The PCAC advisory committee reviews seven peptides (BPC-157, KPV, TB-500, MOTS-c, then DSIP, Semax, Epitalon); five more are expected later.
- • A review is not the rule. PCAC recommends; the FDA then decides separately. Even a move out of Category 2 is not approval.
- • These remain unapproved, investigational. No FDA-approved product, no USP monograph - a gray zone, not a green light.
What "503A" and "Category 2" actually mean
US drug compounding runs on two federal tracks. 503A covers traditional pharmacies compounding for an individual patient; 503B covers larger outsourcing facilities. For a bulk substance to be compounded under 503A without an approved-drug or USP monograph, it generally has to sit on the FDA's 503A bulk drug substances list.
While the agency evaluates nominated substances, it sorts them into buckets. Category 1 is substances that may be used in compounding while under review. Category 2 is the one that matters here: substances the FDA identified as raising significant safety risks, effectively off-limits for compounding. In 2023 the FDA placed roughly 19 peptides, BPC-157 among them, into Category 2, which is why compounding pharmacies had largely stopped supplying them.
What is changing in 2026 - and what is not
In February 2026, HHS signaled an intent to move about 14 of those peptides from Category 2 back toward Category 1, and the FDA scheduled advisory-committee reviews to evaluate them. That is a meaningful shift in direction. But the nuance is the whole story, and it is where most coverage gets ahead of the facts:
- • An announcement is not a rule. As of mid-2026 the Category 2 placements are still formally in effect; the reconsideration is underway, not complete.
- • Category 1 is not approval. Even if these peptides move back to Category 1, that only restores compounding eligibility while under review, it does not make them FDA-approved drugs.
- • Each peptide is evaluated on its own. The committee can recommend for or against, or ask for more data, so they will not necessarily move together.
The honest one-line version: the direction is toward access, the decision is not yet made, and the compounds are still investigational.
The July 23-24, 2026 PCAC review
The next concrete step is the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, which takes up seven peptides for potential 503A eligibility:
| Meeting day | Peptides under review | Commonly used for (unapproved) |
|---|---|---|
| July 23 | BPC-157, KPV, TB-500 (TB4-fragment), MOTS-c | Tissue repair, gut/anti-inflammatory, mitochondrial/metabolic |
| July 24 | DSIP, Semax, Epitalon | Sleep, nootropic, longevity/telomere |
Two things to keep straight. First, PCAC recommends; the FDA decides. A favorable committee vote is an input to a later, separate agency decision on whether a substance lands on the 503A bulks list. Second, this is the first of two expected batches, roughly five additional peptides are slated for a subsequent review, so the full picture will not be settled at a single meeting.
What this means for access right now
Right now, practically nothing has changed at the pharmacy counter. The Category 2 placements remain in effect, so licensed 503A compounding of these peptides is still restricted, and much of the market continues to move through research-use-only (RUO) supply. RUO product carries the same quality-control uncertainty it always has, unverified concentration, purity, and sterility are the real risks, and none of the seven is an approved medicine you can be prescribed as a finished drug product. If the July review and the FDA's follow-on decision eventually restore Category 1 eligibility, licensed compounding could broaden, but that is a future state, not today's.
If you are tracking any of these compounds, the practical implications are unchanged by the regulatory reshuffle: source carefully, assume nothing about concentration without verification, and keep a clean record of what you took and when. That last part is what a tracker is for.
This page summarizes a moving regulatory situation for education; it is not legal or medical advice, and the status can change at or after the July 2026 PCAC meeting and the FDA's follow-on decisions. Every peptide named here is unapproved and investigational - being reconsidered for compounding eligibility does not mean safe, effective, or FDA-approved. Research-use-only supply is not quality-controlled for human use. Do not start, stop, or source anything based on this page; discuss any compound with a licensed clinician, and verify the current FDA status directly before acting.
Keep a clean record of what you run
Regulatory status shifts; your own log shouldn't have gaps. OptiPin tracks every peptide dose, vial, and reconstitution on one on-device timeline - the record a clinician can actually read. iOS only, no account.
Download OptiPinFrequently asked questions
Is BPC-157 legal in the US in 2026?
Its compounding status is in active reconsideration but has not formally changed. BPC-157 was placed in 503A Category 2 in 2023 (removing it from compounding eligibility) and remains unapproved and investigational, with no approved product and no USP monograph. It is not a scheduled controlled substance recreationally, but that is not the same as approved or freely compoundable. The July 2026 review could change eligibility; nothing has taken effect yet.
Did the FDA approve BPC-157?
No. Nothing in the 2026 reconsideration approves BPC-157. There is no FDA-approved product; it remains investigational. A move out of Category 2 would only lift a compounding restriction, not constitute drug approval.
Has the Category 2 status actually changed in 2026?
Not formally. A Feb 2026 HHS announcement signaled intent to move ~14 peptides back toward Category 1, and the FDA scheduled reviews (7 peptides in July 2026, ~5 more expected early 2027). But an announcement and an advisory review are not a final rule; the Category 2 placements stand until the FDA formally acts.
What is the FDA PCAC reviewing in July 2026?
On July 23-24, 2026 the Pharmacy Compounding Advisory Committee reviews seven peptides for 503A eligibility: BPC-157, KPV, TB-500, and MOTS-c (July 23), then DSIP, Semax, and Epitalon (July 24). PCAC recommends; the FDA makes the final decision separately, and about five more peptides are expected in a later review.
Does this affect semaglutide or tirzepatide?
No. GLP-1 medications are approved drugs governed by their own status and FDA shortage lists, a separate track from this research-peptide compounding review. See the GLP-1 guide for the compounded-GLP-1 access picture.
Sources & further reading
- FDA - Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (the categorized list, including Category 1 / Category 2).
- FDA - Pharmacy Compounding Advisory Committee (PCAC) (meeting materials and agendas, including the July 2026 meeting).
- FDA - Compounded drug products are not FDA-approved (why compounded ≠ approved).
- Pharmacy Times - A pharmacist's read on the 2026 peptide reclassification (trade coverage of the announcement and its limits).
Regulatory status is current as of July 2026 and may change at or after the July 23-24 PCAC meeting and subsequent FDA action. Verify the FDA's current position directly before relying on it.
Related
Peptides guide · BPC-157 tracker · TB-500 tracker · BPC-157 science · MOTS-c guide · GLP-1 & compounding